At $14.9 billion, New York-based Pfizer (NYSE: PFE) has beaten estimates for first quarter revenues and raised its profit outlook accordingly.
The firm now expects earnings per share (EPS) to come in at between $2.15 and $2.35, with profits being supported in part by a cost reduction plan.
Reported net income was $3.1 billion, down 44% from the same period of the prior year, while revenues were down 20% compared with 2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze